William Blair believes investors could view Viking Therapeutics (VKTX)’ multi-year manufacturing pact with CordenPharma as a negative to Viking’s takeover prospects. Nonetheless, the analyst ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback